Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus

Christoph D DieterleRüdiger Landgraf


The results of the new immunosuppressants in simultaneous pancreas-kidney transplantation (SPK) concerning organ survival and rejection rates are excellent. Tacrolimus as well as cyclosporine are assumed to be diabetogenic; however, there are no comparative studies investigating their effects on glucose metabolism. One hundred thirty-six type 1 diabetic patients who had undergone successful SPK were investigated. Glucose and insulin levels during an oral glucose tolerance test as well as hemoglobin (Hb) A1c were analyzed. Investigations were performed early (3 months, n = 136) and late (3 years, n = 83) after transplantation. Graft recipients were grouped according to the first-line immunosuppression: group 1, cyclosporine; group 2, tacrolimus. There were no differences concerning age, gender, body mass index, and renal function between the groups. Early after transplantation, there was no difference between the groups concerning fasting glucose, HbA1c levels, basal and stimulated insulin secretion, and incidence of normal glucose tolerance. Late after transplantation, the incidence of a normal glucose tolerance tended to be lower (70% vs. 78%), whereas HbA1c (5.3% vs. 5.0%) and fasting glucose (81 vs. 78 mg/dL) levels tended t...Continue Reading


Feb 14, 1987·British Medical Journal·J J BendingG C Viberti
Dec 27, 1996·Transplantation·R ShapiroT E Starzl
Jun 1, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G FillerB Hocher
Nov 10, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G Bianchi
Mar 5, 2002·Diabetes Care·Victor M MontoriYogish C Kudva
Feb 27, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Bertram L KasiskeArthur J Matas

❮ Previous
Next ❯


Aug 2, 2006·Current Diabetes Reports·Emily C DyKristina I Rother
Jul 18, 2008·Current Diabetes Reports·Elizabeth Diakoff
Oct 25, 2006·Transplantation·Martin L MaiThomas Gonwa
Aug 2, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Elvira O GosmanovaAidar R Gosmanov
Aug 15, 2014·Science Translational Medicine·Thusitha GajanayakeEsther Vögelin
Nov 7, 2007·Endocrinology and Metabolism Clinics of North America·Savitha Subramanian, Dace L Trence
Nov 22, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Christoph D DieterleRüdiger Landgraf
Nov 1, 2006·Life Sciences·Mohammad A AjabnoorAdel Abdulrafee
Feb 24, 2007·Annales d'endocrinologie·M-C VantyghemC Noël

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.